Skip to main content
OpenTrials
Completed

NCT Number: NCT03113448

0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy

To study that 0.075% capsaicin lotion is safe, well tolerated and provide significant pain relief in patients with PDN compared with placebo lotion as a randomized, double- Blind, crossover, placebo-controlled trial

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Thammasat University Hospital

Pathum Thani, 12120, Thailand

About this study

Neuropathy is one of the most common complications in both type 1 and type 2 diabetes mellitus. The most common symptom is a symmetrical, chronic, axonal, length-dependent sensorimotor polyneuropathy.

Topical capsaicin formulations are widely used to manage pain. Low-concentration creams, lotions, and patches intended for daily skin application have been available in most countries since the early 1980s.

We study 0.075% capsaicin lotion is safe, well tolerated and provide significant pain relief in patients with PDN compared with placebo lotion as a randomized, double- Blind, crossover, placebo-controlled trial for 20 weeks throughout the study in 42 participants. All participants are provided both 0.075% capsaicin lotion and placebo lotion. Each agent will be applied for 8 weeks then stop for 4 weeks, after that another agent will be used for 8 weeks. We keep following up all of them by calling and appointment to get information in effectiveness and adverse effect at 0,2,4,8,12,14,16,20 week, respectively.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • DM type 2 over 1 year
  • Clinical presentation of peripheral sensory such as burning pain
  • DN4 score from 4 points
  • Good consciousness to tell their score with informed consent agreement
  • No adding dosage of previous pain control medications at least 4 weeks
  • HbA1C 6.5-9.0%

Exclusion criteria

  • Improper application site of skin for topical drugs such as abrasion wound.
  • Allergic history of Capsaicin
  • No intention to join the study with any reasons
  • Other previous medications used that effect to peripheral neuropathy such as Carboplatin, Cisplatin, Colchicine, Dapsone, Etoposide, Ethambutol, Indomethacin, Isoniazid, Lithium, Metronidazole, Phenytoin, Pyridoxine, Statins, Stavudine (d4T) or conditions worsening peripheral nerves following that poor nutrition, kidney failure, chronic alcoholism, vitamin deficiency, Hypothyroidism

Treatment and study plan

0.075% Capsaicin Lotion

Drug

To apply 3-4 times per day, every day until 8 weeks then stop

Placebo

Drug

To apply 3-4 times per day, every day until 8 weeks then stop

Primary outcomes

  1. Visual analog scale (0-100 mm.)

    Time frame: 20 week

    scale

Secondary outcomes

  1. Short-form McGill Pain Questionnaire(SF-MPQ)

    Time frame: 20 week

    scale

  2. Neuropathic Pain Scale (NPS)

    Time frame: 20 week

    scale

Sponsors and collaborators

Lead sponsor

Thammasat University

Other

Registry information

Official study title

0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy: A Randomized, Double- Blind, Crossover, Placebo-Controlled Trial

Important dates

Study start
2017
Primary completion
2017
Study completion
2018
First posted
Apr 13, 2017
Registry last updated
Sep 12, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.